{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:41Z","timestamp":1791924761950,"version":"4.3.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01614-9","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T13:26:58Z","timestamp":1765027618000},"page":"647-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre"],"prefix":"10.1007","volume":"16","author":[{"given":"Azmeralda","family":"Abraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2775-8192","authenticated-orcid":false,"given":"Neenu","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas C.","family":"Kreeshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish J. A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"3","key":"1614_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","volume":"22","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192\u20139. https:\/\/doi.org\/10.1111\/j.1525-1470.2005.22303.x.","journal-title":"Pediatr Dermatol"},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","volume":"78","author":"L Eckert","year":"2018","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78:54-61.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1614_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1614_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase\u00a03 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"Issue Supplemen","key":"1614_CR5","doi-asserted-by":"publisher","first-page":"ljae266.082","DOI":"10.1093\/bjd\/ljae266.082","volume":"191","author":"E Simpson","year":"2025","unstructured":"Simpson E, Biedermann T, Kircik L, et al. Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 3\u00a0years in week\u00a016 responders. Brit J Dermatol. 2025;191(Issue Supplement_2):ljae266.082. https:\/\/doi.org\/10.1093\/bjd\/ljae266.082.","journal-title":"Brit J Dermatol"},{"key":"1614_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/S40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Tha\u00e7i D, Thyssen JP, et al. Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials. Am J Clin Dermatol. 2023;24:595\u2013607. https:\/\/doi.org\/10.1007\/S40257-023-00792-6.","journal-title":"Am J Clin Dermatol"},{"key":"1614_CR7","doi-asserted-by":"publisher","DOI":"10.25251\/SKIN.9.SUPP.512","volume":"9","author":"J Silverberg","year":"2025","unstructured":"Silverberg J, Ackerman L, Bagel J, et al. Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: results from the ADapt trial. SKIN J Cutan Med. 2025;9:s512\u2013s512. https:\/\/doi.org\/10.25251\/SKIN.9.SUPP.512.","journal-title":"SKIN J Cutan Med"},{"issue":"8","key":"1614_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2217\/fon-2020-0951","volume":"17","author":"B Nazha","year":"2021","unstructured":"Nazha B, Yang JCH, Owonikoko TK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2021;17(8):965\u201377. https:\/\/doi.org\/10.2217\/fon-2020-0951.","journal-title":"Future Oncol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01614-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:31Z","timestamp":1770190831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01614-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Azmeralda Abraheem has received funding to support conference attendance from Novartis. Neenu Sebastian has received funding to support conference attendance from AbbVie and Novartis. Tim H Clayton have no conflicts of interest. Firas C Kreeshan has been a speaker for AbbVie, Almirall, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; received honoraria and\/or consultancy fee and\/or travel bursaries and\/or Educational grants have been from: Abbvie, Almirall, Galderma, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; and been an investigator (Sub-I) for Abbvie, Jansen and Eli Lilly. Hamish JA Hunter has received grant funding from AbbVie, Pfizer, Janssen and Merck Serono; honoraria and\/or consultancy fees and\/or travel bursaries from La Roche-Posay, Janssen, Abbvie, UCB, Sanofi Genzyme, Regeneron, Novartis, Almirall, Leo, Eli Lilly DICE Therapeutics, UNION Therapeutics, Pfizer and Galderma and has acted as an investigator for Janssen, Abbvie, UCB, Sanofi Genzyme, Novartis, Almirall, Leo, Eli Lilly, DICE Therapeutics, UNION Therapeutics, Evelo Biosciences Inc., ONO Pharmaceutical Co. Ltd. Bayer Pharmaceuticals, Artax Biopharma, Sudo Biosciences and No7 Beauty Company. Richard B Warren has acted as a consultant and\/or speaker for and\/or received research grants from AbbVie, Amgen, Almirall, Celgene, Eli Lilly, Pfizer, LEO Pharma, Novartis, Janssen Cilag, Medac, UCB Pharma and Xenoport. Richard B Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data presented was captured in routine clinical care assessing the safety and efficacy of patients using a new therapy in our centre. Additional ethics approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}